StriVectin

StriVectin is a US skincare brand launched in 2002 and built around a patented niacin-derived molecule the company calls NIA-114. It began as a stretch-mark cream sold in health-food stores such as GNC before being repositioned as an anti-wrinkle treatment. The brand is no longer independent: private-equity firm L Catterton invested in it in 2009, and Crown Laboratories acquired it in 2021 [7][8]. Following Crown's 2025 purchase of Revance Therapeutics, the StriVectin site is branded "A Revance Brand" within Crown's consumer skincare portfolio [10].

The brand is positioned in the prestige tier and sells across North America, Europe, the Middle East and Asia through department stores, specialty retailers and its own online store.

StriVectin traces its science to research led by Myron and Elaine Jacobson, a husband-and-wife biochemist team who worked at the University of Arizona and studied niacin's role in DNA repair and skin-cancer prevention [6]. That work produced NIA-114, an optimised form of vitamin B3 the brand markets as an alternative to retinol.

The product itself launched in 2002, made by the privately held company Klein-Becker, a division of the Salt Lake City weight-loss-supplement maker Basic Research. It was first sold as a stretch-mark cream. When customers began applying it to their faces and reported smoother-looking wrinkles, word of mouth grew and department stores picked up the product, prompting its repositioning as an anti-ageing treatment.

The founding date carries a common point of confusion. The brand itself says NIA-114 "was discovered over 35 years ago" during biomedical research, and elsewhere cites "30 years of research" behind the molecule [3]. Those figures describe the underlying niacin science, not the company: StriVectin as a brand launched in 2002.

In 2003 the brand repositioned around anti-ageing and ran print advertising that asked whether StriVectin could be "Better than Botox?" [9]. The question mark was deliberate — framed as a question rather than a direct claim. The marketing drew regulatory attention, and in 2005 the US Food and Drug Administration issued a warning letter over the wrinkle-reducing claims made for StriVectin-SD [12].

L Catterton invested in the brand in 2009. Under chief executive Joan Malloy, hired in 2016, the company scaled back distribution, dropped its hair category and refocused on Generation X consumers; by 2018 it reached profitability with estimated net sales of about $80 million, according to WWD [7]. Crown Laboratories agreed to acquire StriVectin from L Catterton in August 2021 [8]. In February 2025 Crown completed its acquisition of Revance Therapeutics, placing StriVectin alongside brands such as PanOxyl and Blue Lizard within Crown's consumer skincare portfolio [10].

StriVectin has passed through several owners. It began under Klein-Becker/Basic Research, received private-equity investment from L Catterton in 2009, and was acquired by Crown Laboratories in 2021; it now operates within the Crown/Revance group [10]. A note accompanying this entry suggested the French group L'Occitane owned the brand from 2011, but no source supports that: trade press including WWD and PR Newswire records L Catterton's 2009 investment and Crown's 2021 purchase, with no mention of L'Occitane [7][8].

The company describes itself as a science-led skincare maker focused on strengthening and "future-proofing" long-term skin health rather than offering quick fixes. According to StriVectin, its formulas undergo third-party clinical testing, and it presents skincare as "a lifelong journey" backed by science. The brand markets itself in the prestige segment; a 2021 press release described it as "the #1 independent prestige skincare company in the U.S."

NIA-114 is the brand's central ingredient, described as an optimised vitamin B3 the company says is clinically proven to strengthen the skin barrier and appears in every StriVectin formula. The line also features proprietary peptide technologies, including an AI-developed Alpha-3 Peptide and complexes such as Argireline Amplified Peptide, Copper Tripeptide and Turmeric-146 Peptide.

The original StriVectin-SD cream remains the brand's founding product. Its later hero item is the TL Advanced Tightening Neck Cream, marketed as the "#1 neck cream," for which the company cites a claim that 94% of users agreed their neck skin felt firmer. More recent launches include the Peptide Plump Cream.

The brand's early marketing generated legal and regulatory disputes. Beyond the 2005 FDA warning letter, its "Better than Botox?" campaign drew scrutiny and disputes from Allergan, the maker of Botox [12]. In 2006 a class-action lawsuit brought by plaintiff Sarah Morgan named Klein-Becker USA and more than a dozen marketers and distributors, alleging that StriVectin-SD had been falsely advertised as "clinically proven" to reduce wrinkles [9].

StriVectin remains commercially active, with a running e-commerce site, current promotions and ongoing product launches. It is not an independent company: it has been owned by Crown Laboratories since 2021 and now sits within Crown's Revance-branded consumer skincare portfolio. Distribution spans multiple regions across North America, Europe, the Middle East and Asia.